Related Experiment Video
Updated: Mar 31, 2026
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.6K
Inflammasome-Mediated Neuroinflammation: A Key Driver in Alzheimer's Disease Pathogenesis
Julie McGroarty1, Shelbi Salinas1, Hayden Evans1
1Department of Biomedical Sciences, Noorda College of Osteopathic Medicine, 2162 S 180 E, Provo, UT 84606, USA.
Biomolecules
|May 28, 2025
Summary
Alzheimer's disease involves amyloid beta and tau pathology, but neuroinflammation driven by the NLRP3 inflammasome in microglia is a key driver. Targeting this inflammasome offers a promising therapeutic strategy for Alzheimer's disease.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline.
- Hallmark pathologies include amyloid beta (Aβ) plaques and tau tangles.
- Chronic neuroinflammation is increasingly recognized as a critical factor in AD progression.
Purpose of the Study:
- To review the molecular mechanisms of AD.
- To focus on the role of the NLRP3 inflammasome in AD-related neuroinflammation.
- To explore therapeutic strategies targeting the NLRP3 inflammasome.
Main Methods:
- Review of existing literature on AD pathogenesis.
- Analysis of the interplay between Aβ, tau pathology, and microglial activation.
- Examination of NLRP3 inflammasome signaling pathways in the context of AD.
Main Results:
- The NLRP3 inflammasome in microglia is a central mediator of neuroinflammation in AD.
- NLRP3 activation amplifies inflammatory cascades, synaptic dysfunction, and neuronal loss.
- Aβ and tau pathologies modulate NLRP3 inflammasome activity.
Conclusions:
- NLRP3 inflammasome-mediated neuroinflammation is a critical component of AD.
- Targeting the NLRP3 inflammasome presents a promising therapeutic avenue.
- Mitigating neuroinflammation via NLRP3 inhibition may slow AD progression.
Related Concept Videos
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
03:03Amyloid Fibrils
13.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
13.0K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K